stella
beta
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer — Stella
Recruiting
Back to EGFR-mutant Non-small Cell Lung Cancer trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Shanghai Pulmonary Hospital, Shanghai
View full record on ClinicalTrials.gov